News
JANX
16.49
+1.17%
0.19
Weekly Report: what happened at JANX last week (0921-0925)?
Weekly Report · 9h ago
Weekly Report: what happened at JANX last week (0914-0918)?
Weekly Report · 09/21 09:56
Janux Therapeutics: It's Too Early To Tell If Prostate Cancer Program Can Succeed
Seeking Alpha · 09/18 16:46
Janux’s New Prostate Cancer Combo Trial: What Early Signals Could Mean for JANX
TipRanks · 09/17 16:30
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux
NASDAQ · 09/16 09:47
Janux Therapeutics Doses First Patient In The Phase 1 Clinical Trial For JANX013, Its PSMA-Targeted Tumor-Activated CD28 Co-Stimulatory Bispecific, In Patients With Metastatic Castration-Resistant Prostate Cancer
Benzinga · 09/14 12:07
Weekly Report: what happened at JANX last week (0907-0911)?
Weekly Report · 09/14 10:00
Weekly Report: what happened at JANX last week (0831-0904)?
Weekly Report · 09/07 09:55
Janux’s JANX014 Prostate Cancer Trial Advances, Keeping Early-Stage Upside in Play
TipRanks · 09/03 16:32
Weekly Report: what happened at JANX last week (0824-0828)?
Weekly Report · 08/31 10:00
Brinker, Whirlpool, Q32 Bio, Pulte, Janux Trending With Analysts
TipRanks · 08/29 09:00
This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday
Benzinga · 08/24 15:44
Chipotle downgraded, Darden upgraded: Wall Street’s top analyst calls
TipRanks · 08/24 13:55
Janux Therapeutics Price Target Announced at $23.00/Share by Wolfe Research
Dow Jones · 08/24 12:28
Janux Therapeutics Raised to Outperform From Peer Perform by Wolfe Research
Dow Jones · 08/24 12:28
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target
Benzinga · 08/24 12:17
Janux Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
TipRanks · 08/24 10:20
Weekly Report: what happened at JANX last week (0817-0821)?
Weekly Report · 08/24 10:01
Weekly Report: what happened at JANX last week (0810-0814)?
Weekly Report · 08/17 10:01
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Ginkgo Bioworks Holdings (DNA)
TipRanks · 08/13 22:30
More
Webull provides a variety of real-time JANX stock news. You can receive the latest news about Janux Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About JANX
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed three bispecific platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain. Its TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others.